What are the ASCO guidelines for the prevention and treatment of venous thromboembolism (VTE) in cancer patients?

Updated: Nov 05, 2020
  • Author: Vera A De Palo, MD, MBA, FCCP; Chief Editor: Vinod K Panchbhavi, MD, FACS, FAOA, FABOS, FAAOS  more...
  • Print

In May 2013, the American Society of Clinical Oncology (ASCO) released revised clinical practice guidelines on VTE prophylaxis and treatment in patients with cancer. [30]  A review of the literature published from December 2007 to December 2012 was completed in MEDLINE and the Cochrane Collaboration Library, and evidence was assessed to determine which recommendations required revision. Slight changes were made to existing recommendations, and two new recommendations were added that focused on the following:

  • The need to assess and periodically reassess the risk for VTE
  • The need to educate high-risk patients on how to prevent blood clots and how to recognize the warning signs of VTE

The recommendation against the routine use of thromboprophylaxis for most ambulatory patients with cancer remained unchanged. A February 2015 review of 53 publications in MEDLINE and the Cochrane Library by Lyman et al did not find sufficient evidence to prompt a change in the 2013 guidelines. [31]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!